(1R,9S,10S)-17-(cyclopropylmethyl)-4-methoxy-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-13-one

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: (1R,9S,10S)-17-(cyclopropylmethyl)-4-methoxy-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-13-one
• 化学式: C₂₁H₂₇NO₂
• 分子量: 325.4
• InChiKey: TVSUSZBGGNVGHO-HLAWJBBLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Spirocyclic Morphinans and Their Use
  申请人：Purdue Pharma L.P.

  公开号：US20140179724A1

  公开（公告）日：2014-06-26

  The application is directed to compounds of Formula I′-A especially to compounds of Formula I-A and pharmaceutically acceptable salts and solvates thereof, wherein R 1a -R 5a , Y, Z are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I′-A, and especially compounds of Formula I-A, to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.
• SPIROCYCLIC MORPHINANS AND THEIR USE
  申请人：Purdue Pharma L.P.

  公开号：US20150203495A1

  公开（公告）日：2015-07-23

  The application is directed to compounds of Formula I′-A and especially to compounds of Formula I-A and pharmaceutically acceptable salts and solvates thereof, wherein R 1a -R 5a , Y, Z a are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I′-A, and especially compounds of Formula I-A, to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.
• US8987287B2
  申请人：——

  公开号：US8987287B2

  公开（公告）日：2015-03-24
• US9273048B2
  申请人：——

  公开号：US9273048B2

  公开（公告）日：2016-03-01